Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines

Xiao, Zheng; Wang, Cheng-Qiong; Zhou, Mengyun; Hu, Shanshan; Jiang, Yuan; Huang, Xiao-Rong; Li, Nana; Feng, Jing; Tang, Fushan; Chen, Xiaofan; Ding, Jie; Chen, Ling; Wang, Yuhe; Li, Xiaofei

doi:10.1016/j.jep.2018.09.024

Cited by 49 publications

(38 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maintenance chemotherapy refers to systemic therapy for patients with advanced NSCLC if the response is CR, PR, or SD after 4-6 cycles of first-line platinum-based chemotherapy (Gridelli et al, 2012 ). In China, TCM therapy is applied in the whole process of treatment, including conventional and subsequent therapy to maintain efficacy (Wang et al, 2017 ; Xiao et al, 2018 ). Clinically, if a patient with advanced NSCLC who has a performance status (PS) score of 0-2 and shows no disease progression after first line treatment, CHMF can be used in combination with single-agent chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial

et al. 2018

View full text Add to dashboard Cite

Background: Chinese Herb Medicine Formulas (CHMF) was reported to improve the quality of life (QoL) in advanced NSCLC patients. The present study was designed to investigate whether maintenance chemotherapy plus CHMF in patients would improve QoL and progression-free survival (PFS).Methods: Seventy-one patients were enrolled from 8 medical centers in China, and were randomly assigned to a maintenance chemotherapy plus CHMF group (n = 35) or a maintenance chemotherapy plus placebo group (n = 36). The outcome measures included PFS, Karnofsky performance status (KPS) scores, QoL (assessed with the lung cancer symptom scale (LCSS) questionnaire), and adverse events (AEs).Results: Patients in the CHMF group showed significant improvements in median PFS (HR = 0.55, 95% CI 0.28–0.88, P = 0.019), KPS scores (P = 0.047), fatigue (cycle [C] 3: P = 0.03), interference with daily activities (C3: P = 0.04) and dyspnea (C2: P = 0.03) compared with patients in the placebo group. Compared with the placebo group, the incidence of AEs decreased in the CHMF group, including loss of appetite (C2: P = 0.011, C4: P = 0.004) and dry mouth (C4: P = 0.011).Conclusion: The essential finding of our study is that maintenance chemotherapy combined with CHMF may prolong PFS, relieve symptoms, improve QoL and alleviate the side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Included studies > 10, we examined potential publication bias using funnel plot and Egger/Begg's tests. Following our experiences [21,[40][41][42], if the trial with at least one domain considered as high risk, we de ned it as poor quality. In this meta-analysis, and if the result was statistically different and bene t to TPs infusion, we de ned the trial as under-or over-estimated trial.…”

Section: Statistical Analysis and Quality Of Evidencementioning

confidence: 99%

“…Following the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach [44] and our experiences [21,[40][41][42], we sorted evidence quality into four grades as high, moderate, low and very low. The criteria of quality degradation were as follows: (1) limitations in study design (trials had unclear risk, and some trials had high risk, if sensitivity analysis was good robust, the evidence was downgraded by one level; if poor, the evidence was downgraded by two levels; all trials had no high risk, and the evidence was downgraded by one level; and if all were poor, the evidence was downgraded by two levels.…”

Section: Statistical Analysis and Quality Of Evidencementioning

confidence: 99%

Intrathoracic infusion therapy of thymic peptides and chemical irritants for malignant pleural effusion: a meta-analysis of 24 randomized controlled trials

Xiao¹,

Wang²,

He³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: To further determine the clinical efficacy and survival of intrathoracic infusion with TPs and chemical irritants and their therapeutic threshold and optimal control regimen to achieve a desired response in malignant pleural effusion (MPE).Methods: We collected all randomized controlled trials (RCTs) of TPs with chemical irritants from Chinese and English databases (from inception until September 2019), and performed a new metaanalysis following the PRISMA guidelines. We measured their bias risk, summarized data using metaanalysis, and evidence quality using the Grades of Recommendation Assessment, Development and Evaluation approach. Results: We collected 24 trials involving three TPs and platinum and 1,592 patients. Most trials had unclear bias risk. TPs with platinum significantly improved complete response [4.02 (3.12 to 5.18)] and quality of life [3.64 (2.34 to 5.66)], the 0.5-year overall survival (OS) rate [5.75 (3.02 to 10.92)], and 1-year OS rate [5.29, (1.71 to 16.36)], and reduced the treatment failure, myelosuppression, and gastrointestinal toxicity. For patients with moderate to large volume of pleural effusion, KPS score ≥50 to 60, or AST ≥3 months, the thymosin (200-300mg/time), thymopentin (2mg/time) or thymosin alpha 1 (3.2mg/time) with cisplatin (30-40mg/m 2 ), carboplatin (400mg/m 2 ), or oxaliplatin (100mg/m 2 ) are possible regimens for achieving a desired success, and low failure. Most results were robust and moderate quality. Conclusion: The moderate evidence suggests that the TPs with platinum is beneficial to the patient with MPE, and provides evidence for the therapeutic threshold and possible regimens that may achieve a desired success and reduce the failure. Background Malignant pleural effusion (MPE), often originates from most malignant tumors, is a common and challenging problem. Patients often suffer from breathlessness, poor quality of life (QOL) and prognosis [1-2]. Control of the effusion significantly reduces morbidity, and improves quality of life. Chemical pleurodesis is a first-line intervention for MPE without a nonexpendable lung (NEL) [3]. After draining effusion, a chemical irritant such as talc poudrage [4], tetracycline [5], bleomycin [6],

show abstract

“…Based on her own willingness and medical history, after full examinations, we prescribed the treatment of IMRT (intensity‐modulated radiation therapy) to the dose of 60 Gray (for high‐risk area, 30 fractions) and 54 Gray (for low‐risk area, 30 fractions) (Figure A). Meanwhile, administration of Aidi Injection and Compound Kushen Injection (CKI) was given to alleviate pain, enhance immunity, and treat tumor. After the radiotherapy (56 Gray/28 f/36 d), with a slight pain in the oropharynx when swallowing and nausea, she went home for recovery.…”

Section: Case Presentationmentioning

confidence: 99%

Successful treatment of a case with NUT midline carcinoma in the larynx and review of the literature

Zhang¹,

Liu²,

Zhang

et al. 2019

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines

Cited by 49 publications

References 37 publications

Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial

Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial

Intrathoracic infusion therapy of thymic peptides and chemical irritants for malignant pleural effusion: a meta-analysis of 24 randomized controlled trials

Successful treatment of a case with NUT midline carcinoma in the larynx and review of the literature

Contact Info

Product

Resources

About